In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Wins Specialty CV Deal

Executive Summary

Bayer will pay $50 million up front and up to $335 million in development and commercialization milestones for ex-US rights to Nuvelo's clot-buster alfimeprase, which complements the German group's specialist cardiovascular portfolio.

Related Content

Bayer/Regeneron: Typically Rich, Extra Regional
Pharmaceutical Strategic Alliances 2006: Forcing Externalization at Big Pharma
Auctions: Getting the Best Value for Your Asset
The Rise of Regional Dealmaking
FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug
Merck KGAA's Hostile Bid Catalyzes Bayer-Schering Combo
Anatomy of a Deal: Inside the AstraZeneca/ AtheroGenics Agreement
AstraZeneca Joins the In-Licensing Game
AstraZeneca Joins the In-Licensing Game
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts